Murine immunophenotyping and microscopy			
Cell marker	Fluorochrome	Clone	Company
CD45	V450; Alexa Fluor 700	30-F11	BD Biosciences
F4/80	PE; APC	BM8	eBiosciences
Ly6G	APC-Cy7	1A8	BD Biosciences
CD11b	PE-CF594; Alexa Fluor 594	M1/70	BD Biosciences; Biolegend
MHC-II	Alexa Fluor 700	M5/114.15.2	eBiosciences
CD80	V450	16-10A1	BD Biosciences
CD86	APC	GL1	BD Biosciences
CD206	PerCP-Cy5.5	C068C2	BioLegend
CD62L	PE-Cy7	MEL-14	BD Biosciences
IFNγ	PerCP-Cy5.5	XMG1.2	BD Biosciences
TNFα	PE-Cy7	MP6-XT22	BD Biosciences
TGFβ	APC	TW7-16B4	BioLegend
IL-10	V450	JES5-16E3	BD Biosciences
H2Kb (MHC-I)	APC	AF6-88.5.5.3	eBiosciences
H2Kd (MHC-I)	eFluor 450	SF1-1.1.1	eBiosciences
Ovalbumin (OVA)*	FITC	Polyclonal	Abcam/Rockland
Rabbit IgG Isotype*	FITC	Polyclonal	Abcam/Rockland
lgG	Alexa Fluor 594	Polyclonal	Life Technologies
Human immunophenotyping and microscopy			
Cell marker	Fluorochrome	Clone	Company
CD15	BV650; Alexa Fluor 647	HI98; W6D3	BD Biosciences
CD14	BUV395	ΜφΡ9	BD Biosciences
lgG	Alexa Fluor 594	Polyclonal	Life Technologies

Table S1. List of antibodies used for immunophenotyping and microscopy.

\*OVA antibody and isotype from different lots and different manufacturers were used.





**Fig. S1.** Isotype staining control for the localization of Ly6G+ and F4/80+ cells in the myometrial tissues in the second half of pregnancy. BALB/c females were mated with B6 CAG-OVA males, and fetuses with surrounding myometrial tissues were collected at 10.5 days *post coitum* (dpc), 16.5 dpc, or 18.5 dpc. Confocal microscopy imaging of DAPI+CD11b+ cells (indicated by white arrows) with lack of staining for FITC isotype control in the myometrial tissues (100x magnification with digital zoom) (n = 10 each).







**Fig. S2.** Ly6G+ and F4/80+ cells in the myometrial tissues in the second half of pregnancy (OVA antibody staining control) (A & B) BALB/c females were mated with B6 non-CAG-OVA males, and the fetuses with surrounding myometrial tissues were collected at 10.5 days post coitum (dpc), 16.5 dpc, or 18.5 dpc. Representative images of hematoxylin & eosin (H&E) staining (4x magnification), and confocal microscopy imaging of DAPI+CD11b+ cells (indicated by white arrows) with lack of staining for (A) OVA-FITC or (B) isotype-FITC control in the myometrial tissues (100x magnification with digital zoom) (n = 3 each).



Peripheral blood



**Fig. S3. Expression of OVA in maternal circulating T cells in pregnant dams; and proportions of Ly6G+ and F4/80+ cells in the myometrial tissues and maternal circulation from non-pregnant, pregnant, and post-partum dams. (A)** Representative gating strategy for CD4+ and CD8+ T cells within the CD3+ cell population. Grey histograms indicate the isotype control and green histograms indicate OVA antibody staining. T cells do not express the OVA antigen. N = 10. (B) BALB/c females mated with B6 non-CAG-OVA males at 4.5 days *post coitum* (dpc), 10.5 dpc, 16.5 dpc, or 18.5 dpc and postpartum (PP). (C & D) Representative gating strategies and proportions of (B) CD45+Ly6G+OVA+ and (C) CD45+F4/80+OVA+ cells in the myometrial tissues from non-pregnant (NP) dams and dams at 4.5 days dpc, 10.5 dpc, 16.5. dpc, 18.5 dpc and PP (n = 2 each). (E & F) Representative gating strategies and proportions of (E) CD45+Ly6G+OVA+ cells in the maternal circulation (peripheral blood) from NP dams and dams at 4.5 dpc, 10.5 dpc, 18.5 dpc and PP (n = 2 each). Data are shown as box-and-whisker plots where midlines indicate medians, boxes indicate interquartile ranges, and whiskers indicate minimum and maximum ranges.



Fig. S4. Immunophenotyping of fetal antigen-carrying Ly6G+ and F4/80+ cells in the myometrial tissues during mid and late gestation. (A) Flow cytometry gating strategy used to determine the Ly6G+OVA+ and F4/80+OVA+ cells (green histogram) in the myometrium. Proportions of CD11b+Ly6G+OVA+ and CD11b+F4/80+OVA+ cells expressing (B & C) MHC-II, (D & E) CD80, (F & G) CD86, (H & I) CD206, (J & K) CD62L, (L & M) TNF $\alpha$ , (N & O) IFN $\gamma$ , (P & Q) IL-10, or (R & S) TGF $\beta$  in the myometrial tissues at 10.5 days *post coitum* (dpc) and 16.5 dpc (n = 9 – 11 each). Data are shown as box-and-whisker plots where midlines indicate medians, boxes indicate interquartile ranges, and whiskers indicate minimum and maximum ranges. The p-values were determined using Mann-Whitney U-tests.

## Phagocytosis of *Escherichia coli* (Positive control)

![](_page_5_Figure_1.jpeg)

peripheral cells

![](_page_5_Figure_3.jpeg)

Fig. S5. Phagocytosis of *Escherichia coli* by murine maternal Ly6G+ or F4/80+ cells and human maternal CD15+ or CD14+ cells in the second and third trimester of pregnancy. Murine maternal peripheral Ly6G+ or F4/80+ cells and human maternal peripheral CD14+ or CD15+ cells were collected during the second trimester/10.5 days *post coitum* (dpc) or third trimester/16.5 dpc and cultured with pHrodo Green-labelled *Escherichia coli* (*E. coli*) (n = 4 – 6 each). The uptake of labelled *E. coli* by murine Ly6G+ or F4/80+ cells and human CD15+ or CD14+ cells was evaluated by flow cytometry. (A & E) Representative gating strategy showing the uptake of labelled *E. coli* by murine Ly6G+ or F4/80+ cells and human CD15+ or CD14+ cells . Proportions of active (B) murine Ly6G+ and (F) human CD15+ cells or (C) murine F4/80+ and (G) human CD14+ cells that phagocytosed labelled *E. coli*. Data are shown as scatter dot plots where bars indicate the mean and whiskers indicate the standard error of the mean. P-values were determined using Mann-Whitney U-tests. (D) Representative confocal microscopy images showing murine maternal peripheral CD11b+ (indicated in red) cells alone or after phagocytosing green *E. coli*. Blue immunofluorescence indicates DAPI (nuclei). Scale bars represent 10 µm. (H & I) Representative confocal microscopy images showing human maternal peripheral CD15+ or CD14+ cells cells coli, pink indicates CD15, red indicates CD14, and green indicates *E. coli*. Scale bars represent 10 µm.